Common Stock, $0.001 par value per share
- Symbol
- NPCE
- Exchange
- NASDAQ
- Classification
- COMMON
- Status
- Current
Current Report · Items 5.07 · 8-K
Neuropace, Inc.
NPCENASDAQEQUITYCurrent
Submission of Matters to a Vote of Security Holders
Item 5.07 Submission of Matters to a Vote of Security Holders. On June 5, 2026, NeuroPace, Inc. held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”) virtually via live webcast. The following proposals were voted upon, and the final voting results with respect to each such proposal are set forth below.…
Company context
Based in Mountain View, Calif., NeuroPace is a medical device company focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of debilitating seizures. Its novel and differentiated RNS System is the first and only commercially available, brain-responsive platform that delivers personalized, real-time treatment at the seizure source. This platform can drive a better standard of care for patients living with drug-resistant epilepsy and has the potential to offer a more personalized solution and improved outcomes to the large population of patients suffering from other brain disorders.
Current securities
Registered securities in this filing
NeuroPace Inc · 8-K · Filed 2026-06-08
Disclosure sections
Item 5.07Item 5.07 - Submission of Matters to Vote
Item 5.07 Submission of Matters to a Vote of Security Holders.
On June 5, 2026, NeuroPace, Inc. held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”) virtually via live webcast. The following proposals were voted upon, and the final voting results with respect to each such proposal are set forth below. The proposals set forth below are described in detail in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on April 21, 2026.
Proposal 1 - Election of Directors. NeuroPace’s stockholders elected each of the following Class II director nominees to hold office until NeuroPace’s 2029 Annual Meeting of Stockholders and until their successor is duly elected and qualified or until their earlier death, resignation or removal. The results of the vote were:
Nominee For Withhold Broker Non-Votes
─────────────────────────────────────────────────────────────────────────
Lisa Andrade 15,194,450 6,024,133 8,048,133
Scott Huennekens 20,973,382 245,201 8,048,133
Proposal 2 - Ratification of Independent Registered Public Accounting Firm. NeuroPace’s stockholders ratified the appointment of PricewaterhouseCoopers LLP as NeuroPace’s independent registered public accounting firm for the fiscal year ending December 31, 2026. The results of the vote were:
For Against Abstain Broker Non-Votes
──────────────────────────────────────────────────────────────
28,850,105 209,301 207,310 —